Cloud Stocks: Veeva Sees Customer Momentum

Veeva’s Partnerships

Besides product upgrades, Veeva has also been expanding its partnerships. It announced a partnership with Axsome Therapeutics, a biopharmaceutical company that is working on new therapies for the management of central nervous system (CNS) disorders. The partnership will help augment the build of Axsome’s Digital-Centric Commercialization (DCC) platform which is being developed to launch two differentiated CNS investigational medicines. Axsome DCC platform incorporates specialized digital tools, proprietary data and analytics, integrated systems, and an intelligent operating model. The platform will utilize Veeva Commercial Cloud products and services to provide longitudinal patient data to power an efficient, targeted launch. Axsome will have early access to new digital technologies developed by Veeva and will help drive Veeva’s product direction.

Veeva’s stock is currently trading at $271.72 with a market capitalization of $41 billion. It had peaked to a record high of $313.99 in October. It hit a 52-week low of $118.11 in March.

1 2
View single page >> |

Sramana Mitra is the founder of One Million by One Million (1M/1M), a global virtual incubator that aims to help one million entrepreneurs ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.